The report highlights the emerging threat of the presence of xylazine, a nonopioid sedative not approved for human use, in illicitly-made fentanyl (IMF) products. Using data from the Centers of Disease Control and Prevention’s (CDC) State Unintentional Drug Overdose Reporting System (SUDORS), among 20 states and the District of Columbia from January 2019 to June 2022, this report found the monthly percentage of IMF-involved deaths with xylazine detected increased 276% (from 2.9% to 10.9%).

Full Study: https://www.cdc.gov/mmwr/volumes/72/wr/mm7226a4.htm